临床基因组学揭示散发性脑膜瘤的基因变异图谱
本研究对25例原发性和2例复发性脑膜瘤进行500基因面板靶向测序,发现NF2、AKT1、PIK3CA和TRAF7等已知驱动基因突变,以及PI3K亚基、Notch/hedgehog/Wnt通路组分和染色质调控因子等新变异;3例血管瘤型WHO I级脑膜瘤均携带PI3K-AKT通路变异,配对原发与复发非典型脑膜瘤显示SWI/SNF复合体亚基ARID1A和SMARCA4突变克隆富集。
要点
- 500基因面板测序揭示脑膜瘤存在已知驱动基因外的多样基因组变异。
- 3例血管瘤型WHO I级脑膜瘤均含PI3K-AKT信号通路变异。
- 配对原发与复发非典型脑膜瘤显示ARID1A和SMARCA4突变克隆富集。
核心结论
- 在神经肿瘤诊疗中实施靶向基因组学可加深对中枢神经系统肿瘤(包括脑膜瘤)遗传基础的理解。
- 这些分子特征可能在指导治疗策略和患者随访方面具有临床价值。
研究设计与样本
- 对25例原发性脑膜瘤和2例复发性脑膜瘤进行靶向基因组测序,使用包含经典脑膜瘤驱动基因的500基因面板。
- 进一步详述3例血管瘤型脑膜瘤和2例复发性非典型脑膜瘤的基因组图谱及相关临床发现。
主要发现
- 在脑膜瘤样本中发现多样的基因组变异图谱,包括已确立的脑膜瘤相关基因NF2、AKT1、PIK3CA和TRAF7的突变。
- 除已知脑膜瘤驱动基因外,还发现编码其他PI3K亚基、Notch/hedgehog/Wnt信号通路组分和染色质调控因子的基因变异。
- 鉴定出22个在多个样本中发生突变的基因。
- 3例血管瘤型WHO I级脑膜瘤均含有既往被描述为调控肿瘤血管生成的PI3K-AKT信号通路变异。
- 对配对的原创与复发性非典型脑膜瘤分析显示,SWI/SNF复合体亚基ARID1A和SMARCA4突变存在克隆富集。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Meningiomas are the most common primary central nervous system tumor. Previous studies have characterized recurrent genetic alterations that can predict patient prognosis and potentially provide new avenues for therapeutic intervention. Continued efforts to characterize the genomic changes in meningioma samples can aid in the discovery of therapeutic targets and appropriate patient stratification. METHODS: We performed targeted genomic sequencing on 25 primary and 2 recurrent meningiomas using a 500-gene panel, including canonical meningioma drivers. We further detail the genomic profiles and relevant clinical findings in three cases of angiomatous meningiomas and two recurrent atypical meningiomas. RESULTS: Our approach uncovers a diverse landscape of genomic variants in meningioma samples including mutations in established meningioma-related genes NF2, AKT1, PIK3CA, and TRAF7. In addition to known meningioma drivers, we uncover variants in genes encoding other PI3K subunits, Notch/hedgehog/Wnt signaling pathway components, and chromatin regulators. We additionally identify 22 genes mutated across multiple samples. Three patients included in the study were diagnosed with angiomatous WHO grade I meningiomas, all three of which contained variants in the PI3K-AKT signaling pathway previously described to regulate tumor angiogenesis. Analysis of patient-matched primary and recurrent atypical meningiomas revealed clonal enrichment for mutations in the SWI/SNF complex subunits ARID1A and SMARCA4. CONCLUSIONS: Targeted genomics implemented in neuro-oncology care can enhance our understanding of the genetic underpinnings of central nervous system tumors, including meningiomas. These molecular signatures may be clinically useful in dictating treatment strategies and patient follow-up.
引用
- Leclair NK, Shen E, Wu Q, et al. Landscape of genetic variants in sporadic meningiomas captured with clinical genomics. Acta Neurochir (Wien). 2022. PMID: 35881312. doi:10.1007/s00701-022-05316-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。